ClinicalTrials.gg
Active, not recruitingNCT02375841Updated Mar 18, 2026

Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers

An observational study in Brain Cancer and Glioblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
309
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 51 studies in Brain Neoplasms by Memorial Sloan Kettering Cancer Center — 5 open to participants now, 17 under way, none of them phase 3. Brain Neoplasms · Memorial Sloan Kettering Cancer Center.

Started
2015
with 1 other
Observational
8 of 51
1 open now
Primary completion
2027-02
later than 3 of 16 live
Registered
33rd of 51
by date

Among the 51 studies in Brain Neoplasms by Memorial Sloan Kettering Cancer Center, this one is one of 2 that started in 2015, is one of 8 observational ones, reaches primary completion later than 3 of the 16 other live ones, and was the 33rd registered.

Brain Neoplasms

2,447 studies on the registry are indexed under Brain Neoplasms; 546 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

5 of the 51 studies in Brain Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 429 Brain Neoplasms studies recruiting now, 289 (67%) set no upper age limit and 83 (19%) stop at 75 or younger; 80 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Brain Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to learn more about the way physicians communicate with brain tumor patients. This study will look at how oncologists provide information about brain tumors, brain scan results, and treatment options. This study will look at how oncologists provide information about brain tumors, brain scan results, and treatment options. Ultimately, the investigators hope to use these findings to improve communication between patients, caregivers and their doctors.

03

Conditions studied

  • Brain Cancer
  • Glioblastoma

Keywords

  • Communication
  • Physicians
  • Patients
  • Caregivers
  • 15-034
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All patients with GBM will be screened in the outpatient clinic at MSKCC.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient Inclusion Criteria:

  • 18 years or older
  • Pathologic diagnosis of WHO grade IV glioma, as per MSKCC medical record or outside medical record.
  • In the judgment of the consenting professional, proficiency in English that will allow the participant to be able to complete study questionnaires and assessments. Many of the study assessments are available only in English.
  • At the time of consent, orientation to self, place, month and year

Caregiver Inclusion Criteria:

  • 18 years or older
  • Identified by the patient as a relative, friend, or partner with whom he or she has a significant relationship and who provides him or her informal (unpaid) care (i.e., physical or emotional assistance).
  • In the judgment of the consenting professional, proficiency in English that will allow to complete study questionnaires and assessments. Many of the study assessments are available only in English.

Oncologist Inclusion Criteria:

  • Treating Neuro-Oncologist in the Department of Neurology

Exclusion criteria

Exclusion Criteria:

Patient Exclusion Criteria:

  • A patient will be excluded if in the opinion of his/her attending neuro-oncologist or the covering neuro-oncologist, he does not have the capacity to consent to the study based on clinical evaluation
  • Aphasia precluding comprehension and verbalization of consent to participate, in the estimation of the attending physician.

Caregiver Exclusion Criteria:

  • There are no caregiver exclusion criteria.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
309 participants (actual)
Patient registry
No

Groups and cohorts

  • Physicians, Patients, and Caregivers

    This is a longitudinal study of patients with GBM with recurrent or multi-recurrent disease as determined by their neuro-oncologist (on the basis of clinical and/or radiological findings). Patients will indicate a single caregiver who will consent separately and perform separate assessments. The study assessments will evaluate the content of the discussion in which this change in disease status was communicated, as well as include patient-reported and caregiver-reported outcomes. We intend to accrue 160 total participants (80 patients and 80 caregivers) with complete post-discussion visit follow-ups over 18-24 months.

    Behavioral: psychometric tests, questionnaires and neurocognitive assessments

Interventions

  • Behavioralpsychometric tests, questionnaires and neurocognitive assessments
06

What researchers measure

Primary outcomes

  1. number of responses from patients, to 3 yes/no questions

    The curability of the patient's cancer (curability) The patient's prognosis (prognosis)The patient's goals of care should his/her condition worsen and he/she becomes critically ill (EOL)

    Time frame: 2 years

  2. number of responses from caregivers to 3 yes/no questions

    The curability of the patient's cancer (curability) The patient's prognosis (prognosis)The patient's goals of care should his/her condition worsen and he/she becomes critically ill (EOL)

    Time frame: 2 years

  3. number of responses from physicians to 3 yes/no questions

    The curability of the patient's cancer (curability) The patient's prognosis (prognosis)The patient's goals of care should his/her condition worsen and he/she becomes critically ill (EOL)

    Time frame: 2 years

07

Study locations

8 sites
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2015 (actual). Primary completion is estimated for Feb 2027, 144 months after the start.

Of 182 non-industry observational studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 269. This study's planned 144 months is above that.

Counting every sponsor, half of 200 studies reached it within 82 months; a quarter within 41 and three quarters within 269.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2015
First posted
Mar 3, 2015
StartActual
Feb 2015
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02375841
Responsible party
Sponsor
First posted
Mar 3, 2015
Start date
Feb 2015
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Eli Diamond, MD
principal investigator · Memorial Sloan Kettering Cancer Center
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion